These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31668020)

  • 1. Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.
    Meijer TWH; Looijen-Salamon MG; Lok J; van den Heuvel M; Tops B; Kaanders JHAM; Span PN; Bussink J
    Thorac Cancer; 2019 Dec; 10(12):2289-2299. PubMed ID: 31668020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4.
    Meijer TW; Schuurbiers OC; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; Verhagen AF; Lok J; van der Heijden HF; Rademakers SE; Span PN; Bussink J
    Lung Cancer; 2012 Jun; 76(3):316-23. PubMed ID: 22153830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma.
    Schuurbiers OC; Meijer TW; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; van der Drift MA; van der Heijden EH; Oyen WJ; Visser EP; Span PN; Bussink J
    J Thorac Oncol; 2014 Oct; 9(10):1485-93. PubMed ID: 25170642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS.
    Ayyoub M; Memeo L; Alvarez-Fernández E; Colarossi C; Costanzo R; Aiello E; Martinetti D; Valmori D
    Cancer Immunol Res; 2014 Oct; 2(10):943-8. PubMed ID: 24866168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
    Planck M; Isaksson S; Veerla S; Staaf J
    Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients.
    Pan SH; Su KY; Spiessens B; Kusuma N; Delahaye NF; Gruselle O; Myo A; de Creus A; Louahed J; Chang GC; Yu SL; Yang PC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e212-e223. PubMed ID: 27519286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer.
    Meijer TWH; Peeters WJM; Dubois LJ; van Gisbergen MW; Biemans R; Venhuizen JH; Span PN; Bussink J
    Lung Cancer; 2018 Dec; 126():32-40. PubMed ID: 30527190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Koh YW; Lee SJ; Park SY
    Lung Cancer; 2017 Feb; 104():31-37. PubMed ID: 28212997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
    Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
    Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.
    Mahmood MQ; Ward C; Muller HK; Sohal SS; Walters EH
    Med Oncol; 2017 Mar; 34(3):45. PubMed ID: 28197929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
    Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
    Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
    Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.
    Hassanein M; Hoeksema MD; Shiota M; Qian J; Harris BK; Chen H; Clark JE; Alborn WE; Eisenberg R; Massion PP
    Clin Cancer Res; 2013 Feb; 19(3):560-70. PubMed ID: 23213057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.